Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03483675 · ClinicalTrials.gov registry record · Phase 2
Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03483675 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 21 participants.
The verdict
NCT03483675, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This randomized trial studies how well discontinuation or continuation of immunosuppressive therapy works in treating participants with chronic graft versus host disease. Continuation of immunosuppressive treatment may prevent graft-versus-host disease worsening.
Interventions
- OTHER Survey Administration
- BIOLOGICAL Immunosuppressive Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2021-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03483675
The ClinicalTrials.gov registry entry for NCT03483675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Survey Administration is the first listed.
NCT03483675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03483675 about?
NCT03483675 is a clinical study titled "Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease". This randomized trial studies how well discontinuation or continuation of immunosuppressive therapy works in treating participants with chronic graft versus host disease. Continuation of immunosuppressive treatment may prevent graft-versus-host disease worsening.
What is the current status of trial NCT03483675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-06-06. Estimated completion is 2021-03-03.
What interventions are being tested in trial NCT03483675?
The interventions under investigation include: Survey Administration (OTHER), Immunosuppressive Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03483675?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.